President Trump’s December 2025 executive order directed expedited federal rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act to facilitate medical research. In April 2026, the acting attorney general issued an order that immediately moved FDA-approved products and state-licensed medical marijuana into Schedule III while leaving recreational and unlicensed cannabis in Schedule I. The DEA then launched an expedited administrative hearing on broader rescheduling that began June 29, 2026, and was scheduled to conclude by mid-July, with the government presenting as a proponent of the change. Trader sentiment reflects these procedural steps, the hearing record, and any subsequent final rulemaking or court challenges that could determine full implementation timelines.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado$796,329 Vol.
31 mar 2026
30 de septiembre
14%
31 de diciembre
28%
$796,329 Vol.
30 de septiembre
$0 Vol.
14%
31 de diciembre
$186,758 Vol.
28%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.President Trump’s December 2025 executive order directed expedited federal rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act to facilitate medical research. In April 2026, the acting attorney general issued an order that immediately moved FDA-approved products and state-licensed medical marijuana into Schedule III while leaving recreational and unlicensed cannabis in Schedule I. The DEA then launched an expedited administrative hearing on broader rescheduling that began June 29, 2026, and was scheduled to conclude by mid-July, with the government presenting as a proponent of the change. Trader sentiment reflects these procedural steps, the hearing record, and any subsequent final rulemaking or court challenges that could determine full implementation timelines.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado abierto: Feb 7, 2026, 5:04 PM ET
Volumen
$796,329Fecha de finalización
31 mar 2026Mercado abierto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.President Trump’s December 2025 executive order directed expedited federal rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act to facilitate medical research. In April 2026, the acting attorney general issued an order that immediately moved FDA-approved products and state-licensed medical marijuana into Schedule III while leaving recreational and unlicensed cannabis in Schedule I. The DEA then launched an expedited administrative hearing on broader rescheduling that began June 29, 2026, and was scheduled to conclude by mid-July, with the government presenting as a proponent of the change. Trader sentiment reflects these procedural steps, the hearing record, and any subsequent final rulemaking or court challenges that could determine full implementation timelines.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$796,329Fecha de finalización
31 mar 2026Mercado abierto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...President Trump’s December 2025 executive order directed expedited federal rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act to facilitate medical research. In April 2026, the acting attorney general issued an order that immediately moved FDA-approved products and state-licensed medical marijuana into Schedule III while leaving recreational and unlicensed cannabis in Schedule I. The DEA then launched an expedited administrative hearing on broader rescheduling that began June 29, 2026, and was scheduled to conclude by mid-July, with the government presenting as a proponent of the change. Trader sentiment reflects these procedural steps, the hearing record, and any subsequent final rulemaking or court challenges that could determine full implementation timelines.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes